Abstract
Cancer is a complex genetic disease characterized by aberrant cellular behaviors, including uncontrolled growth, invasion, and metastasis. The development of personalized treatment strategies based on genomic profiling has led to improved outcomes. Recent scientific endeavors have focused on targeting cancer through metabolic approaches, capitalizing on the altered metabolic pathways in cancer cells. Glucosodiene polymer, a newly derived compound from glucose, has shown promising results in inhibiting glucose metabolism and modifying the tumor's microenvironment acidity. The Maher Akl Theory "Glucose Mutation" proposes a strategic approach to target cancerous tumors by inhibiting glucose metabolism and altering the tumor's microenvironment acidity using glucose isomer polymers. The goal is to disrupt the metabolic activity of the tumor and potentially modify and control the disease. This manuscript provides an overview of the metabolic vulnerabilities of cancer cells, evaluates the synthesis and chemical structure of glucosodiene, documents its safety, and explores its potential as a targeted therapy for cancer treatment. Additionally, a subset of successful clinical trials is presented, focusing on a case of successful treatment of triple-negative breast cancer (TNBC) with glucosodiene, and Medical Guidance and Integrated Therapeutic Approach: The Protocol of Glucose Mutation Theory via Glucosodiene and indication of Positive Tumor Lysis Syndrome "The potential mechanisms of action of glucosodiene in cancer, including its impact on glucose metabolism, modulation of signaling pathways, and immune-enhancing effects, are discussed.